
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
Wicked Good Cardiometabolic Chat: SGLT2is Offer Cardiorenal Benefits Beyond Diabetes
3
A1c Monitoring Could Be Delayed Up to 2 Years for Patients With Type 2 Diabetes
4
Q&A: The Initiative Bringing Clinical Pharmacy Care to Underserved Patients’ Homes
5




















































































































































